sulfadoxine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
anti-infectives, sulfonamides 2503 2447-57-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fanasil
  • sulfadoxine
  • orthosulfin
  • sulfadoxin
  • sulformethoxine
  • sulformetoxin
  • sulformetoxine
  • sulforthodimethoxine
  • sulforthomidine
A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
  • Molecular weight: 310.33
  • Formula: C12H14N4O4S
  • CLOGP: 1.23
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 116.43
  • ALOGS: -3.02
  • ROTB: 4
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 80.56 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 85 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.064 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.758 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 7.889 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.429 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 19.890 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 29.950 % High 1
herg hERG pIC50 4.117 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.459 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.155 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 8.920 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,GRK3,ITK,JAK1,JAK2,MAP3K21,MAPK7,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2,SIK3,STK33,TEK,TTK 37
kinase-selectivity-class ACVR2A,ACVR2B,AURKA,AXL,CAMK2D,CDK9,DDR1,DYRK1B,EPHB4,ERBB2,GRK2,JAK1,MAP2K3,MAP2K6,MAP3K21,MAP4K1,MAPK7,MARK4,PDK4,PIK3CD,PRKDC,SIK2,SIK3,STK33,TEK,TTK,ULK1 27
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.762 High 1
mh-clint Mouse hepatocyte intrinsic clearance 1.706 High 1
mppb Mouse plasma protein binding (% unbound) 45.290 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.912 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 27.040 % High 1
rh-clint Rat hepatocyte intrinsic clearance 0.652 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 90.520 % High 1
rppb Rat plasma protein binding (% unbound) 10.870 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 990.832 uM High 1

Approvals:

DateAgencyCompanyOrphan
Oct. 28, 1981 FDA ROCHE

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC P01BF09 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
ANTIMALARIALS
Artemisinin and derivatives, combinations
FDA CS M0020790 Sulfonamides
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000892 Anti-Infective Agents, Urinary
MeSH PA D000962 Antimalarials
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
FDA EPC N0000175880 Sulfonamide
CHEBI has role CHEBI:35718 antifungal agent
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:38068 antimalarial
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:75835 anti-anaemic agent

Related Drugs by ATC class:

P01BF Artemisinin and derivatives, combinations 11 drugs
amodiaquineartemetherartemisininartenimolartesunatelumefantrinemefloquinepiperaquinepyrimethaminepyronaridinesulfalene

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chloroquine Resistant Plasmodium Falciparum Malaria indication
Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention indication
Third trimester pregnancy contraindication 41587001
Acute nephropathy contraindication 58574008
Epilepsy contraindication 84757009 DOID:1826
Megaloblastic anemia due to folate deficiency contraindication 85649008 DOID:14026
Kidney disease contraindication 90708001 DOID:557
Anemia due to enzyme deficiency contraindication 111577008
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862
Folic acid deficiency contraindication 190633005
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Porphyria contraindication 418470004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.16 acidic
pKa2 2.46 Basic
pKa3 1.85 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
7,8-dihydro-6-hydroxymethylpterin pyrophosphokinase-dihydropteroate synthase; Dihydropteroate synthetase Kinase INHIBITOR CHEMBL CHEMBL
6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase Enzyme IC50 7.14 IUPHAR

External reference:

IDSource
4017803 VUID
N0000146164 NUI
D00580 KEGG_DRUG
4017803 VANDF
C0038679 UMLSCUI
CHEBI:9329 CHEBI
CHEMBL1539 ChEMBL_ID
DB01299 DRUGBANK_ID
D013413 MESH_DESCRIPTOR_UI
17134 PUBCHEM_CID
10173 IUPHAR_LIGAND_ID
2061 INN_ID
88463U4SM5 UNII
10173 RXNORM
5524 MMSL
d03742 MMSL
002835 NDDF
371431002 SNOMEDCT_US
70570002 SNOMEDCT_US

Pharmaceutical products:

None